Group II and III Ovulatory Disorders Flashcards
what proportion of ovulatory disorders are group II
85%
what are group II ovulatory disorders also called
group II hypothalamic pituitary dysfunction disorders
what clinical features are seen in group II ovulatory disorders
oligo/amenorrhoea, normal gonadotrophins(maybe elevated LH), normal oestrogen, PCOS
how common is polycystic ovary syndrome(PCOS) in females of reproductive age
5-15% of women
what are the Rotterdam diagnostic criteria for PCOS
2 of;
- oligo/amenorrhoea
- polycystic ovaries
- clinical/biochemical signs of hyperandrogenism
describe the USS appearance if polycystic ovaries
12 or more 2-9mm follicles, increased ovarian volume >10ml, unilateral or bilateral
resistance to what hormone is seen in PCOS
insulin resistance(seen in 50-80% PCOS)
describe what insulin resistance in PCOS leads to
hyperinsulinaemia and,
insulin lowers SHBG levels, increasing free/bioavailable testosterone, leads to hyperandrogenism
glucose intolerance(20%)
what are some of the clinical features that can be seen in PCOS
oligo/amenorrhoea, hirsutism, obesity, acne/alopecia
what pre-treatment can be used for group II ovulatory disorders
weight loss if obese, reduce alcohol, stop smoking, folic acid, rubella immunity, normal semen analysis of partner
what are the pharmacological treatment options in the management of group II ovulatory disorders
clomifene citrate tablets, or gonadotrophin therapy(recombinant FSH) daily injections
what is the role of metformin on ovulation induction
15-20% patients don’t ovulate on clomifene, metformin can be used to restore menstruation/ovulation
(also reduces insulin resistance and androgen, increases SBHG)
what are the non-pharmacological treatment options for group II ovulatory disorders
laparoscopic ovarian diathermy(surgery), or IVF
what are the risks of laparoscopic ovarian diathermy
general anaesthetic, ovarian destruction(irreversible)
what are the risks of ovulation induction
ovarian hyperstimulation, multiple pregnancy, theoretical risk ovarian cancer